Medicines regulator not planning to suspend J&J shot after US flags risk of rare neurological condition
Guillain-Barre syndrome is a disorder in which the body’s immune system attacks the nervous system, causing muscle weakness and potential paralysis
14 July 2021 - 20:23
SA’s medicines regulator says it does not anticipate suspending use of the Johnson & Johnson (J&J) coronavirus vaccine after US authorities warned earlier this week of a possible association with a rare neurological condition called Guillain-Barre syndrome.
The J&J shot is one of two vaccines being administered in the national coronavirus inoculation drive and is central to the government’s plans to reach 70% of the adult population by March 2022...
Would you like to comment on this article?
Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Commenting is subject to our house rules.
BL Premium
This article is reserved for our subscribers.
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now